在新西兰使用局部皮质类固醇分发数据的儿童湿疹患病率
Georgina Harvey1, Diana J Purvis2, John M D Thompson3
1Women's and Children's Hospital, Adelaide, South Australia, Australia.
The Australasian journal of dermatology
|July 14, 2024
概括
湿疹影响14%的新西兰儿童,太平洋地区的青少年患病率更高. 这项研究突出了差异,并呼吁进一步研究不同的湿疹患病率.
科学领域:
- 儿科皮肤病学儿科皮肤病学
- 公共卫生监督是对公共卫生的监督.
- 流行病学 流行病学
背景情况:
- 湿疹 (皮炎) 是儿童常见的慢性炎症性皮肤疾病.
- 了解国家流行率对于资源分配和公共卫生倡议至关重要.
- 之前的研究可能没有完全捕捉到新西兰多样化的儿科人口当前的湿疹负担.
研究的目的:
- 确定新西兰0-14岁儿童中湿疹的全国患病率.
- 调查不同种族和社会经济群体中湿疹患病率的变化.
- 为新西兰提供有关儿童湿疹的最新全国数据.
主要方法:
- 进行了以人口为基础的回顾性观察性研究.
- 使用国家药品发行记录用于局部皮质类固醇和软化剂.
- 数据涵盖2006年至2019年所有0-14岁的新西兰儿童.
主要成果:
- 2018年,新西兰儿童 (0-14岁) 中湿疹的总流行率为14.0%.
- 患病率随着年龄的增长而下降,从婴儿 (<1岁) 的26.0%降至老年儿童 (10-14岁) 的8.8%.
- 与毛利儿童 (13.2%) 相比,太平洋儿童的患病率较高 (23.6%).
结论:
- 湿疹是新西兰常见的儿科疾病,影响着很大一部分儿童.
- 太平洋地区的儿童面临的湿疹负担不成比例地高.
- 局部皮质类固醇开放的潜在不平等可能会影响毛利儿童观察到的患病率,需要进一步调查.
更多相关视频
相关概念视频
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
234
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
234
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
267
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
267
Drug Delivery: Miscellaneous Routes
336
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
336
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
114
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
114
Antiasthma Drugs: Leukotriene Modifiers
269
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
269


